Reinhard Ruckser

Medicine · Health Sciences

11h-index600citations57works1.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(14), Cancer Treatment and Pharmacology(13), Hematopoietic Stem Cell Transplantation(8), Cancer Immunotherapy and Biomarkers(5), Acute Myeloid Leukemia Research(5)

Publications56 total

Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2025Open Access
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study
eJHaem·2024Open Access
Randomized comparison between <scp>KTd</scp> and <scp>KRd</scp> induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma
American Journal of Hematology·2024· 4 citedOpen Access
P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)
HemaSphere·2023Open Access
Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2023Open Access
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2023Open Access
Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2023Open Access
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2023Open Access
Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Blood·2022· 1 cited
Kolorektales Karzinom
Wiener Medizinische Wochenschrift·2022· 23 cited
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
Blood·2021· 1 cited
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Cancer Discovery·2021· 197 citedOpen Access
Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond
Cancers·2021· 18 citedOpen Access
Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)
Blood·2020
Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)
Blood·2020
Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial
Blood·2020· 2 cited
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia
European Journal Of Haematology·2020· 16 citedOpen Access
Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)
Blood·2019· 4 cited
PS1470 EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
HemaSphere·2019Open Access
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
Cancers·2018· 97 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

W Hinterberger(15), P Kier(15), Christian Sebesta(14), Niklas Zojer(13), Bernd Hartmann(12), Siegfried Sormann(12), Andreas Petzer(9), Richard Greil(9), Johannes Andel(9), Veronika Buxhofer‐Ausch(8), Hermine Agis(8), Boris Božić(8), Georg Tatzreiter(8), P Zelenka(8), Christoph Tinchon(8), Dominik Wolf‎(7), E Kittl(7), Heinz Ludwig(7), Alexander Egle(7), Maria‐Theresa Krauth(7)